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Summary: 
This phase 1 open-label, non-randomized, dose-adjustment trial showed that single doses of 
primaquine between 0.40 and 0.50 mg/kg were well-tolerated in G6PD-deficient and G6PD-
normal males in Mali, supporting the World Health Organization recommendation on the use of 
single low-dose primaquine to reduce Plasmodium falciparum malaria transmission. 
 
 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy014/4802191
by London School of Hygiene & Tropical Medicine user
on 31 January 2018
Ac
ce
pte
d M
an
us
cri
pt
2 
 
     2 
Malaria Research and Training Centre, Faculty of Pharmacy and Faculty of Medicine and 
Dentistry, University of Science, Techniques and Technologies of Bamako, Bamako, Mali 
(Prof A Dicko, MD; H Diawara, MD; A Mahamar, PharmD; K Sanogo, MD; S Keita, MS; D Kone, 
MD; K Diarra, PharmD; M Djimde, MD) 
 
National University Hospital of Point G, Bamako, Mali (MB Keita) 
 
Department of Epidemiology and Biostatistics, University of California, San Francisco, 
San Francisco, CA, USA (J M Brown, PhD; M Roh, MPH; R Gosling, MD) 
 
Global Health Group, Malaria Elimination Initiative, University of California, San 
Francisco, San Francisco, CA (R Gosling, MD; I Chen, PhD; M Roh, MPH; J Hwang, MD) 
 
School of Medicine, University of California, San Francisco, San Francisco, CA, USA  (M 
Murphy; B Greenhouse, MD) 
President’s Malaria Initiative, Malaria Branch, Division of Parasitic Diseases and Malaria, 
Centers for Disease Control and Prevention, Atlanta, GA USA (J Hwang, MD) 
 
Department of Medical Microbiology, Radboud university medical center, Nijmegen, the 
Netherlands (T Bousema, PhD; H Pett, MSc) 
Institutions: 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy014/4802191
by London School of Hygiene & Tropical Medicine user
on 31 January 2018
Ac
ce
pte
d M
an
us
cri
pt
3 
 
     3 
 
Department of Immunology & Infection, London School of Hygiene & Tropical Medicine, 
London, United Kingdom (T Bousema, PhD) 
 
Department of Clinical Pharmacology, University of Helsinki and Helsinki University 
Hospital, Helsinki, Finland (M Niemi, MD; H Pett, MSc) 
 
Corresponding author:  
Ingrid Chen 
550 16th Street, 3rd Floor 
San Francisco, CA 94158, USA 
Tel: (415) 476-5599 
ingrid.chen@ucsf.edu 
  
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy014/4802191
by London School of Hygiene & Tropical Medicine user
on 31 January 2018
Ac
ce
pte
d M
an
us
cri
pt
4 
 
     4 
ABSTRACT 
Background: The World Health Organization recommendation on the use of single low-dose 
primaquine (SLD-PQ) to reduce Plasmodium falciparum malaria transmission requires more 
safety data. 
 
Methods: We conducted an open-label, non-randomized, dose-adjustment trial of the safety of 
three single doses of primaquine in glucose-6-phosphate dehydrogenase (G6PD)-deficient adult 
males in Mali, followed by an assessment of safety in G6PD-deficient boys ages 11-17 years, 
and 5-10 years, including G6PD-normal control groups. The primary outcome was the greatest 
within-person percentage drop in hemoglobin concentration within 10 days post-treatment. 
 
Results: 51 participants were included in analysis. G6PD-deficient adult males received 0.40, 
0.45, or 0.50 mg/kg of SLD-PQ. G6PD-deficient boys received 0.40 mg/kg of SLD-PQ. There 
was no evidence of symptomatic hemolysis, and adverse events considered related to study 
drug (n=4) were mild. The mean largest within-person percent drop in hemoglobin between day 
0 and 10 was -9.7% (95% CI: -13.5, -5.90) in G6PD-deficient adults receiving 0.50 mg/kg of 
SLD-PQ, -11.5% (95%CI: -16.1, -6.96) in G6PD-deficient boys aged 11-17, and -9.61% (95%CI: 
-7.59, -13.9) in G6PD-deficient boys aged 5-10. The lowest hemoglobin concentration at any 
point during the study was 92 g/L. 
 
Conclusion: SLD-PQ doses between 0.40 and 0.50 mg/kg were well-tolerated in G6PD-d 
males in Mali. 
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BACKGROUND 
The success of malaria control and elimination programs supports global aspirations to 
eradicate human malaria in the coming decades [1]. In order to achieve these ambitions, new 
transmission-blocking tools and strategies are needed. In this context, the use of primaquine 
becomes important, as the only commercially available drug that can stop the transmission of 
Plasmodium falciparum malaria from humans to anopheline mosquitoes.  
 
Primaquine use must be informed by safety considerations, as this drug causes dose-
dependent hemolysis in individuals with enzymatic glucose-6-phosphate dehydrogenase 
(G6PD) deficiency, the most common inherited enzyme deficiency worldwide [2]. Safety 
depends primarily on primaquine dose, as well as the variant of G6PD-deficiency, which varies 
across geographies. In Africa most G6PD-deficiency variants are the mild, A minus variant 
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whilst in Asia, the variants are heterogeneous, with the Mediterranean variant being the most 
severe [3].  
 
For the treatment of P. falciparum gametocytes, the WHO recommends that a 0.25 mg/kg single 
low dose of primaquine (SLD-PQ) be used without G6PD testing, in conjunction with standard 
artemisinin-based combination therapy (ACT), in areas approaching malaria elimination and/or 
facing drug resistance [4, 5]. This WHO recommendation is not backed by systematically 
collected evidence, and the WHO has expressed a need for additional clinical studies focused 
on the safety of SLD-PQ in G6PD-deficient (G6PD-d) individuals [5, 6].  
 
Implementation of the WHO recommendation to use 0.25 mg/kg of SLD-PQ requires that each 
individual be weighed, primaquine tablets be crushed and dissolved in water, and the 
corresponding amount of primaquine solution for the 0.25 mg/kg dose be carefully measured. 
This process is labor intensive, introduces the possibility for dosing errors, and can be avoided 
by the establishment of age-based dosing bands. To develop age-based dosing bands, the 
therapeutic dose range of SLD-PQ, spanning the lowest efficacious dose to the highest safe 
dose in vulnerable individuals, must be established. This provides weight-based dose bands, 
which may then be converted to age-based dosing bands using age-for-weight data [7]. This 
study aims to contribute to the establishment of the higher bound of therapeutic dose range of 
SLD-PQ in African settings. 
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Study design and participants 
This study was an open-label, non-randomized, dose-adjustment followed age de-escalation 
trial of the safety of single dose primaquine in G6PD-d and G6PD-normal (G6PD-n) males in 
Mali without microscopically patent malaria infection. Participants were enrolled sequentially. 
 
In part 1, we investigated three single doses of primaquine in adults: the first was a pre-
specified dose of 0.40 mg/kg in seven G6PD-deficient individuals according to a Carestart™ 3 
rapid diagnostic test (Access Bio, USA), a dose demonstrated to be safe in a previous study [8]. 
The remaining two dose groups were determined by a data safety and monitoring board 
(DSMB), on review of data on adverse events (AEs) and hemoglobin (Hb) concentrations after 
follow-up of at least 10 days for each prior group. The dose was not escalated if any of the 
following occurred: two or more participants experienced acute hemolysis resulting in a Hb drop 
of > 30%, or any participant experienced symptoms requiring blood transfusion or a serious 
adverse event (SAE) related to the study drug by day 10, including acute renal failure and/or 
death. The rationale for choosing a 30% drop was based on a prior study showing that Hb 
concentrations < 70 g/L were associated with fatal anemia; our inclusion criteria ensured that 
starting concentrations of participant Hb were ≥ 100 g/L, thus drops <30% would not pose risks 
to fatal anemia [9]). If none of these criteria were met, the DSMB selected the next dose, which 
could be escalated within a range of 0.05 to 0.2 mg/kg from the last study dose, not to exceed 
0.75 mg/kg. This procedure continued until three dose groups were enrolled. 
 
After enrollment of three dose groups, the DSMB reviewed study data and determined the 
highest dose of primaquine tolerated in part 1, which was then administered to a control group 
METHODS  
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of seven G6PD-n individuals matched within eight years of age to those enrolled in the highest 
tolerable dose group. Follow-up for the control group proceeded in the same manner as the 
intervention groups. G6PD status was validated using semi-quantitative spectrophotometry 
testing (OSMMR-D G-6-PD test, R&D Diagnostics Ltd ®, Greece). 
 
In part 2, we investigated the safety of single dose primaquine in G6PD-d boys, at a dose 0.1 
mg/kg lower than the highest safe dose found in adults, to be conservative. For the first age 
group (11-17 years inclusive), we enrolled seven G6PD-d boys and seven G6PD-n boys 
(control group). Following DSMB review of data using criteria described for part 1, if primaquine 
was safe in this age group, a second age group (5-10 years inclusive) comprised of seven 
G6PD-d and seven G6PD-n boys would be enrolled. 
 
Participants were recruited from the town of Oulessebougou and its surrounding villages in Mali 
by the Malaria Research and Training Centre (MRTC) of the University of Bamako, Mali. Prior to 
recruitment, the study team met with village leaders to arrange for information sessions on the 
trial for prospective participants in the community, seeking informed consent from those 
interested in participation. All individuals that provided consent were tested for G6PD deficiency 
using the Carestart™ 3 test and had their name, address and phone number recorded. Those 
that tested as G6PD-d scheduled a date to visit the study clinic in Oulessebougou for further 
screening, while those with a G6PD-n test result were told they might be contacted at a later 
date for further screening.  
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Eligible participants were males to reduce the possibility of incorrect classification of G6PD 
status using qualitative G6PD tests, known to occur more commonly in heterozygote females 
[10], who provided written informed consent, were able to swallow oral medication, had Hb 
concentrations ≥ 100 g/L assessed by HemoCue® 301 (AB Leo Diagnostics, Helsingborg, 
Sweden), did not have malaria parasitemia according to a thick blood smear on enrolment, and 
agreed to abstain from the ingestion of grapefruit-containing products from 72 hours prior to the 
start of dosing until completion of follow-up. Eligible participants for part 1 of the study were 
aged 18-50 years, and for part 2 of the study, were enrolled based on age group.  
 
Participants who reported any of the following conditions were excluded: a known positive HIV 
and/or hepatitis B test, allergy to primaquine, current use of medication for tuberculosis, HIV, or 
any drugs that have hemolytic potential in G6PD-d individuals (including sulphonamides, 
dapsone, nitrofurantoin, nalidixic acid, ciprofloxacin, methylene blue, toluidine blue, 
phenazopyridine, and co-trimoxazole), use of antimalarial drugs within two weeks before contact 
with the study team, blood transfusion > 500mL within the last three months, high alcohol intake 
(> 14 units of 10 g of alcohol per week) within the past six months, and/or the reported use of 
illicit drugs (marijuana, heroin, cocaine, methamphetamine) within 6 months of study. All eligible 
participants could be enrolled in the study one time, and any enrolled participant that vomited 
within one hour of ingesting primaquine was excluded from analysis.  
 
The study was approved by the Ethics Committee of the Malaria Research and Training Centre 
Faculty of Medicine, Pharmacy and Dentistry of the University of Science, Techniques and 
Technologies of Bamako (N 2015/89/CE/FMPOS), and the Committee on Human Research at 
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the University of California, San Francisco (IRB # 14-14495).  The study was monitored by an 
external clinical trials monitor based in Bamako, Mali. Participants were compensated for time 
and travel. The trial was registered: clinicaltrials.gov NCT02535767. 
 
Procedures  
After collection of day 0 samples, each participant received an oral dose of primaquine 
according to his group assignment, after a fatty snack (biscuits) to minimize gastrointestinal 
symptoms.  The study pharmacist administered primaquine (Sanofi, Laval, QC, Canada) using 
directly observed therapy of 15 mg tablets crushed and dissolved in 15 mL of drinking water, 
administered to the nearest 0.1 mL [11]. 
 
Participants were evaluated at the study clinic at hours 1, 2, 4, 6, 8 and days 1, 2, 3, 4, 5, 6, 7, 
8, 9, 10, 14, and 28 following treatment. On all follow-up days starting approximately 24 hours 
following primaquine administra ion, a clinical exam was conducted, and blood samples were 
taken for Hb measurement and blood slides for malaria and reticulocyte counts (reticulocytosis 
defined as >2.0%). To assess for oxidative stress, a non-invasive methemoglobin measurement 
was taken at all follow-up timepoints using a Masimo Rad-57 pulse oximeter (Masimo, Irvine, 
CA, USA) (methemoglobinemia defined as >3%). Due to technical issues, the pulse oximeter 
was not functional until the start of enrolment of the second dose group. Urine samples were 
also collected on each day of follow-up to assess for hemolysis using a urine color chart 
developed by Hillmen and Hall [12]. If a ≥30% drop in baseline Hb levels was observed by day 7 
of follow-up, a blood sample was taken on day 10 for additional assessment of serum bilirubin, 
urea, and creatinine levels.  
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AEs were assessed actively during all follow-up visits, and passively through the availability of 
study clinicians 24 hours/day, 7 days/week. We recorded the duration and severity of AEs (mild: 
grade 1, moderate: grade 2, severe: grade 3, life threatening: grade 4), relationship to the study 
drug according to study physician(s) (definite, probable, possible, remotely possible, unrelated, 
or unclassifiable), actions taken, and the outcome. AEs were further assessed as serious or not 
serious, according to the treating physician. SAEs were pre-specified in the study protocol and 
adapted by the DSMB prior to trial initiation, defined as any of the following: development of 
clinical signs or symptoms of distress including any requirement for hemodialysis, laboratory 
values of severe hemolytic anemia including a drop in Hb > 40% from baseline levels, a need 
for blood transfusion, the development of hemoglobinuria identified by black coloration in the 
urine associated with a rise in creatinine, and any serious adverse event defined as an 
untoward medical occurrence or effect that at any dose: results in death, is life threatening, 
requires hospitalization, results in persistent or significant disability or incapacity that is clearly, 
probably or possibly related to the study drug. 
 
G6PD testing was conducted using three methods: qualitative phenotypic testing, semi-
quantitative testing, and genotyping. Qualitative phenotypic rapid testing using the Carestart™ 3 
test was conducted for screening throughout the study. Additionally, the field team conducted 
additional qualitative OSMMR tests (OSMMR-D G-6-PD test, R&D Diagnostics Ltd ®, Greece) 
in part 1 after enrollment of the first three individuals, excluding individuals with discordant 
results between the two qualitative tests [13]. Semi-quantitative spectrophotometry testing was 
conducted on all individuals using cryopreserved blood samples (0.1 mL of whole blood) 
collected prior to primaquine administration, and was used to determine final G6PD status for 
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participants for inclusion in analysis. Genotypic testing was conducted for the G6PD G202A 
single nucleotide polymorphisms (SNPs) in all individuals, in addition to A376G SNPs in adults, 
both known to be common among G6PD-d individuals in Africa of the A- variant at the time of 
study design [14]. G6PD-d individuals with any SNPs not assessed for, including 986C later 
identified to be common in Mali, were identified as wildtype in this study [15].  
 
Cytochrome P450 2D6 SNPs were identified for adults, and Polymerase Chain Reaction (PCR) 
methods were used to detect malaria parasites in all participants, using dried blood spots 
collected on filter paper prior to primaquine administration (described in Supplemental Material).  
 
Outcomes 
The primary safety outcome was the largest within-person percent drop in Hb concentration 
between baseline levels (day 0) and day 10 following primaquine administration. Pre-specified 
secondary outcomes consisted of: the incidence of AEs graded by severity and relation to the 
study drug; the occurrence of acute hemolytic anemia at each primaquine dose, including 
absolute and fractional changes in Hb concentration on day 7 and day 28 compared to baseline, 
urine color assessment, reticulocyte count, total and direct bilirubin levels if a within-person Hb 
concentration drop of ≥30% from baseline levels was seen in an individual between day 0 and 7 
(inclusive), methemoglobin concentration, and the development of physical signs or symptoms 
of hemolytic anemia; a comparison between changes in Hb, the frequency and severity of AEs, 
and occurrence of markers of acute hemolytic anemia between G6PD-d and G6PD-n 
participants; and exploratory studies among adults on whether cytochrome P450 2D6 (CYP2D6) 
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SNPs are associated with hemolysis in G6PD-d individuals (described in Supplemental 
Material). 
 
Statistical analysis 
Based on preliminary data, sample size calculations assumed that the average Hb 
concentration before treatment would be 125 g/L, and that the standard deviation for the within-
person change in Hb concentration after treatment would be 17 g/L. Our sample size calculation 
enabled detection of a 15% or greater within-person drop in Hb concentration after treatment 
compared to the null hypothesis of no drop with 80% power and one-tailed a significance level 
of 0.05, requiring 7 individuals per group. This also enabled the detection of a within-person 
drop in Hb concentration of 20% or more among the G6PD-d participants compared to G6PD-n 
controls   
 
For the analysis of change in Hb concentrations, the outcomes were the mean largest within-
person percent drop in Hb concentration between baseline levels and: day 7, day 10, and day 
28 post primaquine treatment. Within age groups (age 5-10, 11-17, and 18+ years), we used a 
regression model adjusting for baseline Hb concentration to determine whether there was a 
significant difference in the outcomes between G6PD-d and G6PD-n participants post 
treatment.  
 
AEs were summarized descriptively for each dosing group, using frequencies of observed 
events, severity, and proportion of participants experiencing at least one event.  
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All analyses were conducted using Stata v12 (StataCorp, College Station, Texas).  
 
RESULTS 
Part 1: 28 adult males were enrolled between August 13 and December 19, 2015 (Figure 1). 
The dose groups of primaquine were 0.40 mg/kg, 0.45 mg/kg, 0.50 mg/kg among G6PD-d 
males, and 0.50 mg/kg in the control group of G6PD-n males (Table 1). The first three 
individuals enrolled in the 0.40 mg/kg group were incorrectly classified as G6PD-d (Carestart™ 
screening test), and were G6PD-n according to semi-quantitative spectrophotometry (excluded 
from analyses, Supplementary Table S1). All G6PD-n individuals were wild-type for both the 
G6PD G202A and A376G allele, most (15/18) G6PD-d individuals had SNPs for the G202A and 
A376G allele and had partial G6PD-d, and 3/18 G6PD-d individuals were identified as wild-type 
but had total G6PD-d according to semi-quantitative spectrophotometry.  
 
Part 2: 28 boys were enrolled between May 12, 2016 and January 10, 2017 (Figure 1). Two 
boys in the G6PD-d, 5-10 age group were misclassified by the Carestart™ screening test and 
were G6PD-n according to semi-quantitative spectrophotometry (excluded from analyses, 
Supplementary Table S3). All G6PD-n boys enrolled were wild-type at the G202A allele. Among 
G6PD-d boys, 7/12 had SNPs at G202A, and 5/12 were identified as wildtype, four of which 
were characterized with partial G6PD-d, and one with total G6PD-d using semiquantitative 
testing.  
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Among men over the age of 18 years (part 1), the mean largest within-person percent drop in 
Hb concentration among G6PD-d individuals receiving the highest tolerable dose of primaquine 
(0.50 mg/kg) was -9.7% (95%CI: -13.5, -5.90) compared to their G6PD-n counterparts who 
experienced a drop of -7.89% (95%CI: --11.4, -4.37) (P=0.320) (Table 2, Supplementary Figure 
S1). Among the boys aged 5-10 years (part 2), the mean largest within-person percent drop in 
Hb concentration among G6PD-d participants was -9.61% (95%CI: -3.08, -16.1), compared to 
their G6PD-n counterparts who experienced a change of -5.24% (95%CI: -0.252, -10.2%) 
(P=0.199). Similarly, among the boys aged 11-17 years (part 2), the mean largest within-person 
percent drop in Hb concentration among G6PD-d participants was -11.5% (95%CI: -6.96, -16.1), 
compared to their G6PD-n counterparts who experienced a drop of -6.89% (95%CI: -2.46, -
11.3) (P=0.072). There was no significant difference between the mean largest within-person 
percent drops in Hb concentration among G6PD-d adult men (n=18; -10.5% (95% CI: -13.3, -
7.6)) and G6PD-d boys aged 5-17 years (n=12; -10.7% (95% CI:-13.9, -7.59, P=0.90)).  
 
The mean largest percent change in Hb concentration was a 16.8% drop between day 0 and 
day 10, which occurred in the group of adult men who received 0.40 mg/kg of SLD-PQ. This 
group included the individual with the largest within-person percent change in Hb concentration 
(23% drop in Hb, A- variant of G6PD deficiency): Hb concentration 147 g/L at baseline and 113 
g/L 9 days following primaquine administration, positive test for P. falciparum malaria at 
baseline by PCR, positive by blood smear on Days 1, 3, 4, 5, 6, 7, symptomatic malaria 
diagnosis on Days 6 through 9 following treatment with primaquine. At Day 28, this participant’s 
Hb concentration was 135 g/L. For all participants enrolled, the lowest absolute value of Hb was 
92 g/L, observed in a six-year old G6PD-d boy: Hb 112 g/L at baseline, nadir observed on day 
10,  no malaria detected by blood smear, and Hb 106 g/L by day 28. 
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During the 28 days of follow-up, no participant experienced a 30% or greater drop in Hb 
(Figures 2 and 3). There were no events of acute hemolysis, severe or SAEs, nor were there 
any symptoms or signs of acute renal failure, hemolytic anemia, hemoglobinurea or 
methemoglobinemia observed. A total of 24 participants (47%) had an AE during follow-up; 
most (44/46 [96%]) were mild (grade 1), 4 of which were considered related to primaquine 
(Table 3). All AEs resolved during study follow-up, and none resulted in stopping participation. 
Thirteen (24%) participants had reticulocytosis, 12 of whom were G6PD-d (Supplementary 
Figure S2). 
 
At the screening visit, although no participants were symptomatic for malaria and all were smear 
negative, PCR analysis of stored blood samples revealed that 41% (21/51) participants had 
asymptomatic malaria parasitemia. During follow-up, a total of 14 participants tested positive for 
malaria on blood smear, with 4 of these 14 being symptomatic (Supplementary Table S4). 
There was no evidence that the within-person change in Hb concentration during follow-up was 
associated with malaria status (Supplementary Figure S3). 
 
DISCUSSION 
This study found that a single dose of primaquine as high as 0.50 mg/kg was well-tolerated 
among G6PD-d adults, and a 0.40 mg/kg dose was well tolerated in G6PD-d adults and 
children. Our study is the first to systematically investigate the safety of SLD-PQ single at doses 
≥ 0.40 mg/kg in G6PD-deficient individuals without malaria, addressing the evidence gap 
identified by WHO Expert Review Group that issued the recommendation to use SLD-PQ. 
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Despite consistent measures of reduced Hb in G6PD-d participants exposed to SLD-PQ 
compared to G6PD normal participants, the reductions in Hb were small and not clinically 
relevant. 
 
This study also provides data to define the therapeutic dose range of SLD-PQ in West African 
settings, which will support field implementation of the WHO recommendation, currently based 
on patient weight and challenged by a requirement to dissolve tablets and carefully measure the 
correct amount of solution to give to the patient [6, 7].  Age-based dose bands were recently 
been modeled for African settings, stating a need for clinical studies to ascertain the therapeutic 
dose range, and preliminarily assuming this to be between 0.1 to 0.4 mg/kg[16]. The lower 
bound of the therapeutic dose range of SLD-PQ is between 0.125 and 0.25 mg/kg, and our 
study suggests that the upper bound may be extended to 0.40 mg/kg in west African settings 
[17-20]. As the severity of G6PD-deficiency can be approximately characterized by geography, 
these results should not be applied to Asian settings. 
 
Other studies to date have focused on the safety of the WHO recommended dose of 0.25 mg/kg 
of SLD-PQ, demonstrated to be safe in Senegal when given with artemether-lumefantrine or 
dihydroartemisinin-piperaquine or artesunate-amodiaquine to 54 phenotypically G6PD-deficient 
malaria patients [21], in Tanzania when given with artemether-lumefantrine to 33 phenotypically 
G6PD-deficient malaria patients [22], and used as mass drug administration at the Thai-
Myanmar border with dihydroartemisinin-piperaquine to 124 phenotypically G6PD-deficient 
individuals [23]. A study investigating the safety of 0.25 and 0.40 mg/kg primaquine in 
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asymptomatic G6PD-d malaria patients in Burkina Faso is complete (NCT02174900) although 
results have not yet been reported.  
 
As malaria infection can reduce hemoglobin concentration, this study was intended to examine 
the isolated effect of primaquine on individuals without malaria. However, many individuals 
enrolled had asymptomatic malaria (40% during screening and 26% during follow-up), four (8%) 
of which presented with symptomatic malaria on follow-up. While it is not possible to determine 
whether Hb drops in these individuals were due to malaria infection or SLD-PQ, the results do 
suggest that SLD-PQ is well-tolerated in G6PD-d individuals, both with and without malaria.  
 
The main limitations to this study include a small sample size, as well as the exclusion of 
women, and vulnerable individuals who were already anemic on enrolment, an ethical 
precaution taken to ensure the safety of study participants. As SLD-PQ is now being rolled out 
in various countries in Africa, furth r assessment of its safety should be carried out using 
pharmacovigilance mechanisms, including emphasis on vulnerable individuals who are anemic, 
have HIV and/or tuberculosis infection, and/or are unaware of their pregnancy when they take 
primaquine.  
 
In summary, these results provide evidence towards extending the upper bound of the 
therapeutic dose range of SLD-PQ to 0.40 mg/kg in sub-Saharan Africa, evidence which may be 
applied to facilitate the age-based dosing of SLD-PQ in sub-Saharan Africa. 
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The findings of this study have been presented at the American Society of Tropical Medicine 
and Hygiene 2015 Annual meeting, Philadelphia, PA. Symposium: “Primaquine for falciparum 
malaria: where are we, what do we know, what do we need to know?” (AD presented, IC was 
session chair). The findings were also presented at American Society of Tropical Medicine and 
Hygiene 2016 Annual meeting, Atlanta, GA. Poster No.1536: “Safety of single dose primaquine 
in G6PD-deficient adult males in Mali without malaria: an open-label phase 2 dose-adjustment 
trial.” (IC presented). 
 
Disclaimer: The findings and conclusions in this report are those of the author(s) and do not 
necessarily represent the official position of the U.S. Centers for Disease Control and 
Prevention. 
 
Figure Legends: 
 
Figure 1. Trial profile. Primaquine was given as a single dose on the day of enrolment. All enrolled individuals 
completed the study; none were lost to follow-up. G6PD = glucose-6-phosphate dehydrogenase, PQ = 
primaquine. 
 
Figure 2. Part 1 hemoglobin concentration (g/L) over 28 days of follow-up by primaquine dose group: within-
person percent change from baseline (2a), within-person change from baseline hemoglobin concentration (2b), 
and absolute hemoglobin concentration (2c), Boxplot key: median (line) IQR (box), and range (whisker) 
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Figure 3. Part 2 hemoglobin concentration (g/L) over 28 days of follow-up by enrollment group (G6PD 
status and age) : within-person percent change from baseline (3a), within-person change from baseline 
hemoglobin concentration (3b), and absolute hemoglobin concentration (3c), Boxplot key: median (line) IQR 
(box), and range (whisker) 
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Table 1. Baseline characteristics of participants overall and by primaquine treatment group 
Part 1: dose adjustment in adult males 
  
Primaquine treatment group in G6PD-d males 
Control group 
G6PD-n 
Baseline characteristics Overall 0.40 mg/kg 0.45 mg/kg 0.50 mg/kg 0.50 mg/kg 
Number of participants 25 4 7 7 7 
Age (years), mean [range] 35 [18,50] 29 [18, 50] 35 [26, 50] 37 [25, 47] 37 [28, 43] 
Weight (kg), mean [range] 63.0 [44.2, 83.0] 55.8 [44.2, 70.1] 60.5 [52, 74.4] 62.9 [56.8, 68.5] 69.9 [59.9, 83.0] 
Hemoglobin results at baseline 
(g/L) 
149 [120, 175] 138 [120, 151] 152 [144, 175] 151 [136, 162] 150 [136, 165] 
Part 2: age de-escalation in boys given 0.40 mg/kg primaquine 
Baseline characteristics Overall 
Age group 
5-10 years of age 11-17 years of age 
G6PD-d G6PD-n G6PD-d G6PD-n 
Number of participants 26 5 7 7 7 
Age (years), mean [range] 10 [5, 17] 7 [5, 8] 7 [5, 9] 13 [11, 16] 13 [11, 17] 
Weight (kg), mean [range] 28 [16, 48] 20 [17, 24] 23 [18, 29] 35 [29, 44] 35 [25, 48] 
Hemoglobin results at baseline 
(g/L) 
123 [102, 145] 117 [108, 142] 119 [102, 145] 127 [121, 130] 130 [116, 142] 
 
 
 
  
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy014/4802191
by London School of Hygiene & Tropical Medicine user
on 31 January 2018
Ac
ce
pte
d M
an
us
cri
pt
24 
 
     24 
Table 2. Mean within-person percent change in hemoglobin (Hb) concentration by treatment group: the largest drop between Days 0 and 10 (a), the change between Day 
0 and 7 (b), and the change between Day 0 and 28 following treatment with primaquine. And (d) the mean day of study follow-up when the largest Hb drop occurred.  
  A. Largest Hb drop between Day 0 
and Day 10 
B. Hb drop from Day 0 to Day 7 C. Hb drop from Day 0 to Day 28 
D. Mean day of study follow-up 
when largest Hb drop occurred 
Primaquine treatment groups 
% change*, 95% CI P** % change*, 95% CI P** % change*, 95% CI P** Study day, 95% CI 
Part 1: dose adjustment in adult males 
Control group  
(G6PD normal, 0.50 mg/kg; n=7) 
-7.89 (-11.4, -4.37) -- -2.13 (-8.10, 3.84) -- -2.49 (-6.88, 1.91) -- 7.9 (5.0, 10.8) 
0.40 mg/kg group (G6PD-
deficient, n=4) 
-16.8 (-24.7, --8.93) <0.001 -7.53 (-19.2, 4.11) 0.009 -1.00 (-19.4, 17.4) 0.215 7.0 (3.6, 10.4) 
0.45 mg/kg group (G6PD-
deficient, n=7) 
-7.63 (-12.5, -2.75) 0.662 -4.62 (-10.9, 1.68) 0.587 -2.33 (-8.99, 4.32) 0.638 9.4 (1.6, 17.2) 
0.50 mg/kg group (G6PD-
deficient, n=7) 
-9.72 (-13.5, -5.90) 0.320 -3.77 (-9.77, 2.23) 0.606 -0.754 (-6.67, 5.16) 0.481 7.7 (3.9, 11.5) 
Part 2: age de-escalation in boys given 0.40 mg/kg primaquine 
0.40 mg/kg G6PD-normal, 11-17 
years old (n=7) 
-6.86 (-11.3, -2.46) -- 0.314 (-3.69, 4.31) -- -0.662 (-5.23, 3.90) -- 9.0 (0.9, 17.1) 
0.40 mg/kg G6PD-deficient, 11-
17 years old (n=7) 
-11.5 (-16.1, -6.96) 
 
-6.89 (-10.5, -3.30) 0.006 -6.59 (-13.5, 0.300) 0.111 13.4 (4.0, 22.8) 
0.40 mg/kg G6PD-normal, 5-10 
years old (n=7) 
-5.24 (-10.2, -0.252) -- 4.46 (-3.01, 11.9) -- 1.89 (-6.62, 10.4) -- 7.6 (-1.8, 16.9) 
0.40 mg/kg G6PD-deficient, 5-10 
years old (n=5) 
-9.61 (-16.1, -3.08) 0.199 0.017 (-13.2, 13.3) 0.378 -1.02 (-11.9, 9.89) 0.407 11.4 (4.1, 18.7) 
*Negative values indicate drops in hemoglobin. 
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**P-values adjusted for baseline value of Hemoglobin. Within age groups, we used a regression model adjusting for baseline hemoglobin to compare G6PD-d 
and G6PD-n participants. 
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Table 3. Adverse Events 
Part 1: dose adjustment in adult males 
 Primaquine treatment group in G6PD-d men Control group 
  0.40 mg/kg 
(n=4) 
0.45 mg/kg  
(n=7) 
0.50 mg/kg 
(n=7) 
0.50 mg/kg G6PD-n 
(n=7) 
Participants with an adverse event, n 
(%) 
4 (100%) 4 (57%) 2 (29%) 2 (29%) 
Number of adverse events 4 8 2 2 
Number of drug related 0 0 0 0 
Cough, Mild 0 3 0 0 
Fever, Mild 1 0 0 0 
Headache, Mild 1 1 0 1 
Headache, Moderate 0 0 1 0 
Insect bites, Mild 0 1 0 0 
Rhinobronchitis, Mild 0 1 0 1 
Skin boil, Mild 0 0 1 0 
Symptomatic malaria, Mild 2 2 0 0 
Part 2: age de-escalation in boys given 0.40 mg/kg primaquine 
 Age group 
 5-10 years of age 11-17 years of age 
 G6PD-d G6PD-n G6PD-d G6PD-n 
Participants with an adverse event, n 
(%) 
2 (40%) 6 (86%) 3 (43%) 1 (14%) 
Number of adverse events 8 18 4 1 
Number of drug related 1 2 1 0 
Abdominal pain, Mild 2 6 0 0 
Adenopathy, Mild 0 1 0 0 
Back pain, Mild 1 0 0 0 
Conjunctivitis, Mild 0 0 0 1 
Dental pain, Mild 
Mild 
0 1 0 0 
Diarrhea, Mild 0 0 1 0 
Ear infection, Mild 0 1 0 0 
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Fever, Mild 0 1 1 0 
Headache, Mild 0 1 1 0 
Injury in big toe, Mild 0 2 0 0 
Irregular heartbeat, Mild 0 1 0 0 
Loss of appetite, Mild 1 0 0 0 
Nasopharyngitis, Mild 0 3 0 0 
Runny nose, Mild 1 0 0 0 
Skin boil, Moderate 0 0 1 0 
Sore throat, Mild 0 1 0 0 
Vomiting, Mild 3 0 0 0 
There were no severe or serious adverse events. There were no adverse events that caused stopping rules. All events were self-reported. Mild events 
were defined as those causing no or minimal interference with usual social and functional activities. Moderate events as those causing greater than 
minimal interference. Severe events as those causing inability to perform usual social and functional activities. 
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Figure 1. 
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Figure 2. 
 
  
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy014/4802191
by London School of Hygiene & Tropical Medicine user
on 31 January 2018
Ac
ce
pte
d M
an
us
cri
pt
32 
 
     32 
Figure 3. 
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